• Zenas BioPharma CEO Leon O. Moulder Jr. reported an indirect purchase of 60,000 common shares at a weighted average price of $16.88.
• Indirect beneficial ownership tied to the reported holdings totaled 96,928 shares following the transaction.
• Separately disclosed positions included 1.79 million shares held indirectly, with 423,155 shares held directly.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-063362), on May 18, 2026, and is solely responsible for the information contained therein.